Risk of cancer, autoimmunity, and thrombosis in G-CSF–treated PBSC donors vs BM donors. (A) Incidence of reported cancer after donation (excluding nonnelanoma skin cancer). (B) Incidence of reported nonmelanoma skin cancer after donation. (C) Incidence of reported autoimmunity after donation. (D) Incidence of reported thrombosis after donation.